Compare Citius Pharmaceuticals Inc (CTXR) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Old Dominion Freight Line Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Old Dominion Freight Line Inc trades at $182.34 (market cap $37.68B). The key difference: Old Dominion Freight Line Inc is far larger — about 2766.5× Citius Pharmaceuticals Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Old Dominion Freight Line Inc for 76 Days on average.
| CTXR | ODFL | |
|---|---|---|
Market Cap | $13.62M | $37.68B |
Volume | 132,438 | 1,550,104 |
Sector | Health | Industrials |
52-Week High | $1.82 | $248.73 |
52-Week Low | $0.48 | $126.29 |
Typical Hold Time | 17 Days | 76 Days |
Enterprise Value | $3.79M | $37.42B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
ODFL trades at $181.39, up 3.29% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 19.44% net income margin and 24.82% ROE, though revenue has trended down from $6.3B in 2022 to $5.5B in 2025. A recent 4.9% general rate increase effective October 5, 2026, aims to support margins amid cost pressures.
Valuation remains elevated with a P/E of 34.95, posing a risk if growth slows. Analyst consensus is mixed with a $230.93 price target implying 27% upside, but competitive and macroeconomic headwinds in the trucking industry require careful monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
